Organisation: Roivant Sciences

IAM’s Market Makers of 2023

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

$7 billion Roivant deal would be ultimate vindication of its pioneering IP commercialisation model

The company’s distinctive dealmaking approach has produced many successes to date

28 July 2023

Myovant $2.9 billion buyout is the product of smart IP deal-making

The company’s high value was produced by a series of innovative patent transactions

27 October 2022

Takeda continuing divestment spree by monetising unwanted oncology IP

The Japanese company is leading the pack in trend of commercialising de-prioritised assets

30 September 2022

The five hub-and-spokes models transforming pharma IP commercialisation

Several approaches have emerged under this banner, each offering advantages and disadvantages

15 August 2022

Pure Storage’s patent team reveals strategy; how REATISS responded when Ukraine was invaded; Nokia wins German SEP injunction; plus much more

Get ready for the new working week with a summary of all the stories posted on the IAM platform over the past seven days

10 July 2022

Pfizer to commercialise its IP with the help of trailblazing Roivant approach

The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space

04 July 2022

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

$1.9 billion transaction is another boost for non-core IP deal-making in pharma

Sierra Oncology buyout is motivated by previously unwanted drug asset it bought for a $3 million upfront fee

15 April 2022

Platform technology owners demand a chunk of Moderna’s covid-19 revenues

Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator

07 March 2022